REDEMPLO

Launch

plozasiran

Arrowhead Pharmaceuticals
NDASUBCUTANEOUSSOLUTION
Approved
Nov 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
9

Mechanism of Action

Pharmacologic Class:

APOC-III-directed RNA Interaction

Clinical Trials (5)

NCT06880770Phase 3Recruiting

Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

Started Apr 2025
288 enrolled
Severe Hypertriglyceridemia
NCT06822790Phase 3Recruiting

Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

Started Apr 2025
869 enrolled
Hypertriglyceridemia
NCT06347016Phase 3Active Not Recruiting

Study of Plozasiran in Adults With Severe Hypertriglyceridemia

Started Jul 2024
311 enrolled
Severe Hypertriglyceridemia
NCT06347003Phase 3Active Not Recruiting

Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

Started Jul 2024
446 enrolled
Severe Hypertriglyceridemia
NCT06347133Phase 3Active Not Recruiting

Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Started May 2024
1,456 enrolled
Hypertriglyceridemia

Loss of Exclusivity

LOE Date
Sep 10, 2038
152 months away
Patent Expiry
Sep 10, 2038

Patent Records (5)

Patent #ExpiryTypeUse Code
10294474
Mar 7, 2037
SubstanceProduct
U-4360
11174481
Mar 7, 2037
SubstanceProduct
—
10597657
Sep 10, 2038
SubstanceProduct
U-4360
11214801
Sep 10, 2038
SubstanceProduct
U-4360
12365899
Sep 10, 2038
SubstanceProduct
U-4360
Company
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals
PASADENA, CA
4 open jobs
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers